title: Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis.
abstract: We report a patient with non-small cell lung cancer (NSCLC) developed leptomeningeal carcinomatosis (LMC) after 4 years of multiple treatments. High-dose tyrosine kinase inhibitor (TKI) was given for LMC at first but was not effective. She then received dual therapy combining of afatinib and cetuximab. Brain magnetic resonance imaging (MRI) showed a partial response of disease and the patient experienced a clinical benefit. Our case suggests that dual targeting of epidermal growth factor receptor (EGFR) by a combination of afatinib and cetuximab can be a potential novel treatment option in treating LMC when high-dose TKI failed.
authors.affiliation: Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
authors.forename: Chou-Han
authors.initials: CH
authors.lastname: Lin
authors.affiliation: Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
authors.forename: Ming-Tzer
authors.initials: MT
authors.lastname: Lin
authors.affiliation: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
authors.forename: Yao-Wen
authors.initials: YW
authors.lastname: Kuo
authors.affiliation: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: ccho1203@gmail.com.
authors.forename: Chao-Chi
authors.initials: CC
authors.lastname: Ho
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000077716:Afatinib; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology; D000068818:Cetuximab; D066246:ErbB Receptors / Q000235:genetics; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D008279:Magnetic Resonance Imaging; D055756:Meningeal Carcinomatosis / Q000175:diagnosis / Q000209:etiology*; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000556:secondary; D009154:Mutation; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000209:etiology*; D011799:Quinazolines / Q000008:administration & dosage
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D011799:Quinazolines; D000077716:Afatinib; D066246:ErbB Receptors; D000068818:Cetuximab
keywords: Afatinib; Cetuximab; EGFR; Leptomeningeal carcinomatosis; Non-small cell lung cancer; Tyrosine kinase inhibitor